TY - JOUR
T1 - FGF23 effects on the heart—levels, time, source, and context matter
AU - Faul, Christian
N1 - Funding Information:
CF was supported by the R01HL128714 grant from the National Institutes of Health and by the 1-16-IBS-087 award from the American Diabetes Association.
PY - 2018/7
Y1 - 2018/7
N2 - Fibroblast growth factor 23 (FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality, as suggested by a variety of clinical studies, or additionally acts as a causative factor that induces cardiac injury, as more recently indicated by cell culture and animal studies, is under debate and the center of many ongoing experimental studies.
AB - Fibroblast growth factor 23 (FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality, as suggested by a variety of clinical studies, or additionally acts as a causative factor that induces cardiac injury, as more recently indicated by cell culture and animal studies, is under debate and the center of many ongoing experimental studies.
UR - http://www.scopus.com/inward/record.url?scp=85048723774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048723774&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2018.03.024
DO - 10.1016/j.kint.2018.03.024
M3 - Comment/debate
AN - SCOPUS:85048723774
VL - 94
SP - 7
EP - 11
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 1
ER -